Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Sarepta Therapeutics's Enterprise Value is $2,469 Mil.
Sarepta Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $111 Mil. Therefore, Sarepta Therapeutics's EV-to-OCF for today is 22.24.
The historical rank and industry rank for Sarepta Therapeutics's EV-to-OCF or its related term are showing as below:
SRPT'
s EV-to-OCF Range Over the Past 10 Years
Min: -81.43 Med: -13.66 Max: 117.14
Current: 22.24
During the past 13 years, the highest EV-to-OCF of Sarepta Therapeutics was 117.14. The lowest was -81.43. And the median was -13.66.
SRPT's EV-to-OCF is ranked worse than 89.39% of 1404
companies
in the Biotechnology industry
Industry Median: -3.65
vs SRPT: 22.24
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sarepta Therapeutics's PE Ratio (TTM) for today is calculated as:
Sarepta Therapeutics's share price for today is $20.94.
Sarepta Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.900.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sarepta Therapeutics EV-to-OCF Related Terms
Sarepta Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Sarepta Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sarepta Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sarepta Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's EV-to-OCF falls into.
Sarepta Therapeutics's current Enterprise Value is $2,469 Mil.
Sarepta Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $111 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics (SRPT) has a EV-to-OCF of 22.24 as of Sep. 09, 2026. According to the industry distribution chart, Sarepta Therapeutics ranks #1255 out of 1404 companies in the Biotechnology industry, placing it in the top 89.4%.
Is Sarepta Therapeutics' EV-to-OCF too high?
Sarepta Therapeutics' current EV-to-OCF is 22.24. Based on the distribution chart, Sarepta Therapeutics ranks #1255 out of 1404 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sarepta Therapeutics has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' EV-to-OCF compare to AUPH and PVLA?
According to the Biotechnology industry distribution chart, Sarepta Therapeutics ranks #1255 out of 1404 companies for EV-to-OCF. This places Sarepta Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Sarepta Therapeutics's current EV-to-OCF is 22.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (SRPT) is currently considered Possible Value Trap. The stock's GF Value™ is $108.97, compared to a current price of $20.94 — trading 80.8% below its estimated fair value. The current EV-to-OCF is 22.24. Sarepta Therapeutics' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Sarepta Therapeutics (SRPT), the current EV-to-OCF is 22.24 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sarepta Therapeutics (SRPT) Overvalued in 2026?
Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued.
The current stock price of $20.94 is trading 80.8% below its estimated GF Value™ of $108.97.
GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.
Key valuation signals for SRPT:
EV-to-OCF: 22.24
GF Value™: $108.97 vs. price of $20.94 (80.8% below fair value)
No single metric tells the full story. See the SRPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
59GF Score
Get the complete analysis for SRPT
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRPT has been successfully added to your 
